From January 2020 Cancer Treatment and Research Communications is an open access journal.
Authors who publish in Cancer Treatment and Research Communications will be able make their work immediately, permanently, and freely accessible.
Cancer Treatment and Research Communications authors will pay an article publishing charge (APC), have a choice of license options, and retain copyright to their published work.
Cancer Treatment and Research Communications is an international peer-reviewed publication dedicated to providing comprehensive basic, translational, and clinical oncology research.
The journal is devoted to articles on detection, diagnosis, prevention, policy, and treatment of cancer and provides a global forum for the nurturing and development of future generations of oncology scientists.
Cancer Treatment and Research Communications publishes comprehensive reviews and original studies describing various aspects of basic through clinical research of all tumor types.
The journal also accepts clinical studies in oncology, with an emphasis on prospective early phase clinical trials.
Specific areas of interest include basic, translational, and clinical research and mechanistic approaches; cancer biology; molecular carcinogenesis; genetics and genomics; stem cell and developmental biology; immunology; molecular and cellular oncology; systems biology; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; cancer policy; and integration of various approaches.
Our mission is to be the premier source of relevant information through promoting excellence in research and facilitating the timely translation of that science to health care and clinical practice.
Abstracting & Indexing
ScopusGoogle ScholarDirectory of Open Access Journals (DOAJ)Web of ScienceMedlineEmbase
Detailed Metrics
Total Docs. (latest)
153
Total Docs. (3 years)
357
Total Refs.
7,521
Total Citations (3 years)
1,289
Citable Docs. (3 years)
356
Citations / Doc. (2 years)
3.49
Ref. / Doc.
49.16
% Female
43.8%
Metrics Visualization
Latest year data vs 3-year cumulative figures
Female: 43.8% |
Male: 56.2%
Citations / Doc. (2yr)3.49
Average
References / Doc.49.16
High refs
Citable / Total Docs (3yr)99.7%
Publication & Citation Trend
Loading trend data from Crossref...
Top 10 Most Cited Articles
Loading articles...
Frequently Asked Questions
What is the impact factor of Cancer Treatment and Research Communications?
The official Journal Impact Factor (JIF) is published by Clarivate in the Journal Citation Reports (JCR) and is not listed on this page. Based on SCImago data, Cancer Treatment and Research Communications has an SJR of 0.995 and is ranked Q2.
What is the SJR and quartile of Cancer Treatment and Research Communications?
Cancer Treatment and Research Communications has an SJR (SCImago Journal Rank) of 0.995 and its best quartile is Q2.
What is the H-index of Cancer Treatment and Research Communications?
The H-index of Cancer Treatment and Research Communications is 35, meaning 35 of its articles have each been cited at least 35 times.
Is Cancer Treatment and Research Communications indexed in Scopus?
Yes. Cancer Treatment and Research Communications is active in Scopus (Scopus Source List, August 2026).